- Rius, M& Lyko, F. (2012). Epigenetic cancer therapy: Rationales, targets and drugs. Oncogene, 31, 4257-4265.
The article is focused on research in cancer therapy. Regarding the fact that the most effective cancer treatment is based on the epigenetic regulatory enzymes action, the scientists have focused their analysis on four approved drugs against cancer that refer to two different drug classes. Among such, the influence of the histone deacetylase inhibitors and the DNA methyltransferase inhibitors on tumorigenesis was examined. As a result, the interest in azanucleosides metabolization pathways, cellular uptake and the development of DNTM inhibitors of the second generation was renewed. Moreover, the molecular understanding of cancer was altered because of mutations associated with DNA methylation. The findings of the research are quite informational and to some extent even revolutionary for the development of the effective epigenetic drugs.
- Stein, R.A.& Davis, D.L. (2012). Epigenetics: A fascinating field with profound research, clinical, & public health implications. The American Biology Teacher, 74(4), 213-216.
The article deals with research in the sphere of epigenetics. There are numerous evidences that this biomedical sphere as well as genetic peculiarities of organisms is very influential for the disease development, diagnostic, prophylactic and treatment studies. However, there are some biological cases that genetics fails to explain. For instance, such bright example is the monozygotic twin pairs that made the scientists pay attention to a number of non-genetic factors that contribute to diseases. Consequently, the authors offer some explanations and examples of how the epigenetic factors together with environmental and genetic ones contribute to carcinogenesis. As a result, the findings of the article prove that any cancer therapeutic application is to regard all the impacts and factors altogether in order to reach the higher effectiveness in the disease treatment.
- Bellido, R., Blanco, J., Cabrera, C., Coaklei, E., Codoner, F.M., Clotet, B., Curriu, M., Dalmau, J., Daumer, M., Lie, Y., Martinez-Picado, J., Noguera-Julian, M., Paredez, R., Perez-Alvarez, S., Pou, C., Puig, J., Thielen, A. (2013). HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: Diagnostic accuracy, viral evolution and compartmentalization. Plos One, 8, 1-13.
The article presents the findings of the experimental testing of the patients infected with HIV-1. Evaluation of the HIV-tropism in the PBMCs and plasma can be done with the help of several clinical testings. However, the virological response to CCR5 can be predicted only in plasma trials. For this reason, it is important to define the level of the different clinical testings effectiveness. Considering the fact that CCR5 therapy is highly dependent on the accurate HIV-1 tropism characterization, the purpose of the study was to check the informativeness of the ESTA, MT-2, Slatkin-Meddison tests. The results showed that plasma and PBMCs can show similar tropism indicators. However, the proviral DNA testing of tropism needs specific validation because viral populations and tropism diagnostics are sometimes different considering various compartments. For this reason, the proviral tropism DNA testing not always can be applied to average clinical decision-making while plasma HIV-1 tropism assessing stays the optimal routine testing strategy in the clinical experiences.